Desmosine and isodesmosine (lung elastin degradation products usually elevated in COPD patients but also in AATD patients) were reduced after long-term intravenous AT and possibly with nebulized therapy52. Use of CT densitometry in disease monitoring has been vital in proving an effect of AT in emphysema10, and lower CT density has also been related to mortality in AATD patients with basal emphysema, while FEV1 and DLCO alone have a weaker relationship11. Although these are rare associations, they are plausible, since AAT is anti-inflammatory and immunomodulatory47,49; thus, in AATD, enhanced risk of inflammatory and autoimmune diseases could occur. CB, as part of the spectrum of neutrophilic inflammation in the lungs, might be one of the clinical features that should draw attention to AATD diagnosis2. AATD lung disease is characterized by basal pan-lobular emphysema at an early age, though a range of other phenotypes have been recognized (Figure 2).
The progression of emphysema is related to the age at which smoking began, as well as to the lifetime smoking history.9,34,35 In a recent study, the frequency of variant alleles was described in 30,827 individuals who might have some deficiency were evaluated-by buccal swab or by dried blood spot (DBS) sampling (collection of a blood drop on filter paper)-between 2018 and 2022 in six countries (Argentina, Brazil, Chile, Colombia, Spain, and Turkey). Mutations in the SERPINA1 gene lead to different changes in the AAT glycoprotein, which can alter its concentration, conformation, and function.5,13 More than 200 variants of the SERPINA1 gene have been described.14 The AAT variants initially found were classified with letters from A to Z, depending on the speed of migration of the molecule in a pH gradient after isoelectric focusing.
France and Germany have the most patients receiving AAT-AT (around 60%), whereas in Spain only approximately 20% of patients are receiving treatment25. In cases of severe chronic hypoxemia at rest, long-term oxygen therapy improves survival, and if chronic hypercapnia is also present, long-term non-invasive ventilation might decrease hospitalizations and mortality, as in usual COPD58. Most AATD patients’ management is based on COPD prevention and maintenance therapy. This suggests that densitometry may be a useful clinical tool in AATD; however, clinical heterogeneity, lack of longitudinal data, and inter-individual lung volume variation are some of the limitations in the wide adoption of this technology. Usually lung function is used to evaluate the progression and deterioration of AATD14.
In symptomatic individuals with an AAT test showing no variants, genetic sequencing should be requested, because they might be carriers of a null variant, in which case, serum AAT will be undetectable.2 The specific treatment should not be discontinued even if the FEV1 falls below 25% of the predicted value. Treatment with AAT replacement has an indefinite duration, is costly, and requires careful consideration. In the RAPID-OLE study, at the end of a second 24-month period (i.e., at 48 months after the start of the trial), those who continued to receive AAT replacement had lost 5.03 g/L, whereas those who had received placebo for 24 months and the received AAT replacement for 24 months had lost 6.32 g/L.
The plasma degradation product of fibrinogen (Aα-Val360) was a disappointing marker, lacking a linear progression with time when considering its relationship between disease activity and severity, although it does reduce with augmentation53. The measurement of pulmonary emphysema through CT densitometry has become more common in recent research. Written informed consent was obtained from the patient/patient’s family for the use and publication of the clinical image (ia). The pulmonary microbiota in AATD patients differs from that of usual COPD smoking patients. PLCH is strongly linked with cigarette smoking, manifests in young adults, and is characterized by the presence of polycystic lung lesions. The relationship between asthma and AATD is unclear, although it has been proposed38 that patients tested and diagnosed with AATD at an early age are more likely to be labeled as asthmatic28. Written informed consent was obtained from the patient/patient’s family for the use and publication of these clinical images.
Many people with Alpha-1, especially if they don’t smoke, can live a normal life span. Gene mutations that change the shape of AAT keep it from moving out of your liver. Elastin gives strength to the small air sacs of your lungs (alveoli) and allows them to stretch and contract, like a rubber band. After elastase has had time to help fight an infection, AAT shuts it off (inhibits) so it won’t damage your lungs.
We summarize the last 5–10 years’ key findings in AATD diagnosis, assessment, and management, with a focus on milder deficiency variants. Different types of biological markers have been suggested for disease monitoring and therapy selection, although most need further investigation. Together, you can make a plan to improve your symptoms, reduce your risk of complications and have the best quality of life. Augmentation therapy can slow the progression of emphysema. If you have emphysema due to very low levels of Alpha-1 in your blood, they may recommend augmentation therapy. If you have a mutation in just one of your copies of the gene (carrier), your body can usually make enough functioning AAT to protect your lungs. Lung diseases caused by Alpha-1 have symptoms similar to chronic obstructive pulmonary disease (COPD).
BEAM-302 is a lipid nanoparticle-delivered base editing therapy designed to correct the PiZ mutation in the SERPINA1 gene, enabling production of normal AAT in liver cells. Clinical outcomes such as lung function or liver histology have not yet been reported. Your tax-deductible donation funds lung disease and lung cancer research, new treatments, lung health education, and more. If your healthcare provider suspects AAT deficiency is affecting the liver, the provider may order blood testing of liver function and in some cases an ultrasound of the liver. Lung and liver transplantation are reserved for severe and terminal cases of AATD.96 After liver transplantation, AATD is corrected because the phenotype-normal donor liver produces and secretes AAT. When AAT replacement is indicated, it should follow the criteria described in this document.1,9,108,114 Experience with lung volume reduction surgery in patients with AATD is limited. It is interesting to use questionnaires to assess quality of life, assess COPD, and monitor exacerbations.9,105 Despite the cost, AAT replacement is a specific treatment that will slow the destruction of the lung parenchyma, consequently increasing survival,108 and should therefore be offered to all those who need it.
The elevated SHBG is explained by his early liver derangement, and while our subject did not proceed to liver biopsy, it is highly likely that he is affected by AATD-related hepatitis. We believe that the hypogonadal symptoms in our subject relate to a compensated hypogonadal state with elevated SHBG leading to decreased bioavailability of testosterone and rising gonadotrophin levels. No abnormalities of libido or secondary sexual characteristics were previously described. Hypogonadism is not classically described in this condition; however, abnormalities of the gonadal axis hormone pattern have previously been well documented,14 including elevated total testosterone and SHBG but lower free testosterone as well as higher gonadotrophin levels compared with controls.

Gender: Female

Social links